IL6 and HIV infectious disease: Furthermore, NRTIs+INSTIs patients also showed similar levels of IL-6, VCAM and ICAM to the controls, suggesting that this regimen is able to counteract the increased BT induced by HIV infection and also diminish systemic inflammation, potentially reducing future HIV-related complications (such as cardiovascular events) triggered by BT and inflammation.